-
Abbott India's Net Profit Rises 13.6% to Rs 328.8 Cr in Q3 FY23
Abbott India's consolidated net profit growth was driven by a 10.2% increase in sales in the quarter, which reached Rs 1,734.7 crore.
-
Abbott India Launches Freestyle Libre 3 Continuous Glucose Monitoring System in India
The Freestyle Libre 3 system is a cutting-edge glucose monitoring technology that provides real-time glucose readings without the need for fingersticks.
-
Abbott India Receives Approval for Acquisition of Solvay's Global Established Pharmaceuticals Business
The acquisition will strengthen Abbott's position in the Indian market and expand its product portfolio in key therapeutic areas.
-
Abbott India's Q2 FY23 Net Profit Jumps 22.7% to Rs 293.8 Crore
The company's revenue grew by 13.9% to Rs 1,621.7 crore in the quarter, reflecting strong growth across its key business segments.
-
Abbott India Launches New Heart Failure Drug Corlanor in India
Corlanor is a once-daily medication approved for the treatment of chronic heart failure in adults.
-
Abbott India Q4 net profit rises 10.3% to Rs 219.6 crore
Abbott India on Monday reported a 10.3 per cent increase in its net profit to Rs 219.6 crore for the quarter ended March 2023, mainly driven by sales growth across all its businesses. The company had posted a net profit of Rs 199.1 crore in the corresponding quarter of the previous fiscal.
-
Abbott India to acquire Alere Inc.'s India business
Abbott India will acquire the India business of Alere Inc. for Rs 321 crore, the company said in a statement. The acquisition will add Alere's rapid diagnostics business to Abbott's existing portfolio of diagnostic products and services in India.
-
Abbott India launches FreeStyle Libre 3, its most advanced continuous glucose monitoring system
Abbott India has launched FreeStyle Libre 3, its most advanced continuous glucose monitoring (CGM) system to date. The FreeStyle Libre 3 system is designed to help people with diabetes manage their condition more effectively.
